Skip to Main Content

Alzheimer’s

Here you’ll find the latest on Alzheimer’s disease, from research developments and clinical trials to the policy debates surrounding new drugs and treatments. Alzheimer’s disease is the most common cause of dementia and is the sixth leading cause of death in the United States.

Latest

Biotech Jonathan Wosen

STAT Plus: Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines

Health Jonathan Saltzman — Boston Globe

STAT Plus: ‘I’m still here’: Before Alzheimer’s, he prided himself on his intellect

Biotech Jason Mast

STAT Plus: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial

First Opinion Adina Wise

Who should get to see the neurologist first: the sick or the at-risk?

In the Lab Timmy Broderick

Alzheimer’s drug may raise the risk of brain bleed in patients with Down syndrome

First Opinion Mike Zuendel

Phasing out the ‘D-word’

In the Lab Associated Press

Blood tests for Alzheimer’s diagnosis were 91% accurate in new study

First Opinion P. Murali Doraiswamy and Lon S. Schneider

Survey: Neurologists split on prescribing new Alzheimer’s treatments

All Coverage

Health Jonathan Wosen

STAT Plus: New study bolsters evidence rare genetic mutation can delay early Alzheimer’s

In the Lab Alia Sajani

How a Baltimore neuroscience study is rewriting Black America’s relationship with medical research

advertisement

The Readout LOUD Adam Feuerstein and Allison DeAngelis

STAT Plus: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)

Biotech Elaine Chen and Adam Feuerstein

STAT Plus: FDA advisers unanimously recommend approval of Eli Lilly’s Alzheimer’s disease treatment

Biotech Matthew Herper and Elaine Chen

STAT Plus: FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group

First Opinion Carolyn Clevenger

Outdated Medicare rules prevent some dementia patients from getting the medications they need

Biotech Matthew Herper

STAT Plus: Getting Alzheimer’s treatment to those who need it poses particular challenges

STAT Events Megan Molteni

STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment

The Readout Elaine Chen

STAT Plus: Vertex starts gene therapy Casgevy in five patients

Biotech Adam Feuerstein

STAT Plus: Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede

Health Care Inc. Bob Herman

Medicare expects a big spike in spending on Leqembi

The Readout Damian Garde

STAT Plus: Gas prices are hurting biotech

Exclusive Bob Herman and Rachel Cohrs Zhang

STAT Plus: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025

The Readout Meghana Keshavan

STAT Plus: Preventing the weaponization of AI-designed proteins

Biotech Andrew Joseph

STAT Plus: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug

Biotech Adam Feuerstein

STAT Plus: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Biogen Alzheimer’s drug launch off to slow start

Letters to the editor Torie Bosch

What STAT readers think about Aduhelm, CTE and the Super Bowl, and more

First Opinion Jason Karlawish

STAT Plus: Aduhelm was a mess — and it could happen again

The Readout Meghana Keshavan

STAT Plus: What makes a drug a blockbuster — or a cautionary tale?

Biotech Damian Garde

STAT Plus: Years after a polarizing approval, Biogen walks away from Aduhelm